These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29979514)

  • 21. Synthesis of New Benzimidazole-1,2,3-triazole Hybrids as Tyrosinase Inhibitors.
    Mahdavi M; Ashtari A; Khoshneviszadeh M; Ranjbar S; Dehghani A; Akbarzadeh T; Larijani B; Khoshneviszadeh M; Saeedi M
    Chem Biodivers; 2018 Jul; 15(7):e1800120. PubMed ID: 29766648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ligand-based design, synthesis and biochemical evaluation of potent and selective inhibitors of Schistosoma mansoni dihydroorotate dehydrogenase.
    Calil FA; David JS; Chiappetta ERC; Fumagalli F; Mello RB; Leite FHA; Castilho MS; Emery FS; Nonato MC
    Eur J Med Chem; 2019 Apr; 167():357-366. PubMed ID: 30776695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors.
    Sainas S; Pippione AC; Lupino E; Giorgis M; Circosta P; Gaidano V; Goyal P; Bonanni D; Rolando B; Cignetti A; Ducime A; Andersson M; Järvå M; Friemann R; Piccinini M; Ramondetti C; Buccinnà B; Al-Karadaghi S; Boschi D; Saglio G; Lolli ML
    J Med Chem; 2018 Jul; 61(14):6034-6055. PubMed ID: 29939742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery a series of novel inhibitors of human dihydroorotate dehydrogenase: Biological activity evaluation and molecular docking.
    Ren X; Liu X; Hua M; Dai Y; Ren X; Sui C; Li X; Jiang Z; Tian M; Yang B
    Chem Biol Drug Des; 2024 Jan; 103(1):e14388. PubMed ID: 37926553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural basis for the design of selective inhibitors for Schistosoma mansoni dihydroorotate dehydrogenase.
    Nonato MC; de Pádua RAP; David JS; Reis RAG; Tomaleri GP; D'Muniz Pereira H; Calil FA
    Biochimie; 2019 Mar; 158():180-190. PubMed ID: 30664899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of potent substrate-based inhibitors of the Trypanosoma cruzi dihydroorotate dehydrogenase.
    Inaoka DK; Iida M; Hashimoto S; Tabuchi T; Kuranaga T; Balogun EO; Honma T; Tanaka A; Harada S; Nara T; Kita K; Inoue M
    Bioorg Med Chem; 2017 Feb; 25(4):1465-1470. PubMed ID: 28118956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and inhibitory activity against human dihydroorotate dehydrogenase (hDHODH) of 1,3-benzoazole derivatives bearing amide units.
    Li J; Wu D; Xu X; Huang J; Shao X; Li Z
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3064-3066. PubMed ID: 27220723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and biological evaluation of kojic acid derivatives containing 1,2,4-triazole as potent tyrosinase inhibitors.
    Xie W; Zhang J; Ma X; Yang W; Zhou Y; Tang X; Zou Y; Li H; He J; Xie S; Zhao Y; Liu F
    Chem Biol Drug Des; 2015 Nov; 86(5):1087-92. PubMed ID: 25916324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.
    Cogan DA; Aungst R; Breinlinger EC; Fadra T; Goldberg DR; Hao MH; Kroe R; Moss N; Pargellis C; Qian KC; Swinamer AD
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3251-5. PubMed ID: 18462940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis of 2-,4,-6-, and/or 7-substituted quinoline derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents: 3D QSAR-assisted design.
    Vyas VK; Qureshi G; Oza D; Patel H; Parmar K; Patel P; Ghate MD
    Bioorg Med Chem Lett; 2019 Apr; 29(7):917-922. PubMed ID: 30738663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel series of teriflunomide derivatives as orally active inhibitors of human dihydroorotate dehydrogenase for the treatment of colorectal carcinoma.
    Li C; Zhou Y; Xu J; Zhou X; Huang Z; Zeng T; Yang X; Tao L; Gou K; Zhong X; Chen Q; Luo Y; Zhao Y
    Eur J Med Chem; 2022 Aug; 238():114489. PubMed ID: 35640328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dihydroorotate dehydrogenase inhibitors: quantitative structure-activity relationship analysis.
    Ren S; Wu SK; Lien EJ
    Pharm Res; 1998 Feb; 15(2):286-95. PubMed ID: 9523317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.
    Coteron JM; Marco M; Esquivias J; Deng X; White KL; White J; Koltun M; El Mazouni F; Kokkonda S; Katneni K; Bhamidipati R; Shackleford DM; Angulo-Barturen I; Ferrer SB; Jiménez-Díaz MB; Gamo FJ; Goldsmith EJ; Charman WN; Bathurst I; Floyd D; Matthews D; Burrows JN; Rathod PK; Charman SA; Phillips MA
    J Med Chem; 2011 Aug; 54(15):5540-61. PubMed ID: 21696174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis of beta-hydroxy-propenamide derivatives and the inhibition of human dihydroorotate dehydrogenase.
    Kim TH; Na HS; Löffler M
    Arch Pharm Res; 2003 Mar; 26(3):197-201. PubMed ID: 12723931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase.
    Boa AN; Canavan SP; Hirst PR; Ramsey C; Stead AM; McConkey GA
    Bioorg Med Chem; 2005 Mar; 13(6):1945-67. PubMed ID: 15727850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery and biological evaluation of some (1H-1,2,3-triazol-4-yl)methoxybenzaldehyde derivatives containing an anthraquinone moiety as potent xanthine oxidase inhibitors.
    Zhang TJ; Li SY; Yuan WY; Wu QX; Wang L; Yang S; Sun Q; Meng FH
    Bioorg Med Chem Lett; 2017 Feb; 27(4):729-732. PubMed ID: 28131711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis of some novel heterocylic compounds derived from 2-[3-(4-chlorophenyl)-5-(4-methoxybenzyl)-4H-1,2,4-triazol-4-yl]acetohydrazide and investigation of their lipase and α-glucosidase inhibition.
    Bekircan O; Ülker S; Menteşe E
    J Enzyme Inhib Med Chem; 2015 Dec; 30(6):1002-9. PubMed ID: 25640970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel insights for dihydroorotate dehydrogenase class 1A inhibitors discovery.
    Cheleski J; Rocha JR; Pinheiro MP; Wiggers HJ; da Silva AB; Nonato MC; Montanari CA
    Eur J Med Chem; 2010 Dec; 45(12):5899-909. PubMed ID: 20965617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural and Biochemical Features of
    Sato D; Hartuti ED; Inaoka DK; Sakura T; Amalia E; Nagahama M; Yoshioka Y; Tsuji N; Nozaki T; Kita K; Harada S; Matsubayashi M; Shiba T
    Genes (Basel); 2020 Dec; 11(12):. PubMed ID: 33297567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of 7-arylaminopyrazolo[1,5-a]pyrimidines as anti-Plasmodium falciparum, antimalarial, and Pf-dihydroorotate dehydrogenase inhibitors.
    Azeredo LFSP; Coutinho JP; Jabor VAP; Feliciano PR; Nonato MC; Kaiser CR; Menezes CMS; Hammes ASO; Caffarena ER; Hoelz LVB; de Souza NB; Pereira GAN; Cerávolo IP; Krettli AU; Boechat N
    Eur J Med Chem; 2017 Jan; 126():72-83. PubMed ID: 27744189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.